Search Results for:

EMA Adopts Positive Opinion for Amgen's Eculizumab Biosimilar Candidate BEKEMV®

European Medicines Agency

On February 23, 2023, the European Medicines Agency (EMA) adopted a positive opinion for BEKEMV®.  BEKEMV® is a biosimilar candidate referencing Alexion’s biological product SOLIRIS® (eculizumab), which is a recombinant humanized monoclonal IgG2/4κ antibody that binds to the human c5 complement protein.  SOLIRIS® is approved for the treatment of paroxysmal…

Read More

Deal Watch: Henlius Licenses Rituximab and Trastuzumab Products to Abbott in Brazil

Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac®), two products developed by Henlius, in Brazil.  According to the announcement, Abbott will pay…

Read More